Treatment satisfaction with Omnipod DASH in adults with type 1 diabetes: A non-blinded 1:1 randomized controlled trial.
- Resource Type
- Academic Journal
- Authors
- Kong YW; Diabetes Technology Research Group, The University of Melbourne, Melbourne, Victoria, Australia.; Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.; Yuan CY; Diabetes Technology Research Group, The University of Melbourne, Melbourne, Victoria, Australia.; Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.; Kiburg K; Diabetes Technology Research Group, The University of Melbourne, Melbourne, Victoria, Australia.; Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.; Brown K; Diabetes Technology Research Group, The University of Melbourne, Melbourne, Victoria, Australia.; Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.; Trawley S; Diabetes Technology Research Group, The University of Melbourne, Melbourne, Victoria, Australia.; Cairnmillar Institute, Camberwell, Victoria, Australia.; Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.; Partovi A; Keylead Health, Melbourne, Victoria, Australia.; Roem K; Diabetes Technology Research Group, The University of Melbourne, Melbourne, Victoria, Australia.; Pham C; Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.; Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia.; The Australian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne, Melbourne, Victoria, Australia.; Harrison N; Geelong Endocrinology and Diabetes, Geelong, Victoria, Australia.; Fourlanos S; Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.; Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.; The Australian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne, Melbourne, Victoria, Australia.; Ekinci EI; Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.; Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia.; The Australian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne, Melbourne, Victoria, Australia.; O'Neal DN; Diabetes Technology Research Group, The University of Melbourne, Melbourne, Victoria, Australia.; Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.; Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.; The Australian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne, Melbourne, Victoria, Australia.
- Source
- Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1945-7197 (Electronic) Linking ISSN: 0021972X NLM ISO Abbreviation: J Clin Endocrinol Metab Subsets: MEDLINE
- Subject
- Language
- English
Objective: We compared treatment satisfaction with a tubeless insulin pump (Omnipod DASH® Insulin Management System) to usual care (multiple daily injections [MDI] or tubed insulin pump therapy [IPT]) in adults with type 1 diabetes using self-monitoring blood glucose (SMBG).
Research Design and Methods: Adults with type 1 diabetes on MDI (n = 40) or IPT (n = 25) from four diabetes centers in Australia were randomized in a 1:1 non-blinded manner to Omnipod DASH System (Omnipod group) or continue usual care (Usual Care group) for 12 weeks, followed by a further 12-week extension where all participants used the device. The primary outcome was treatment satisfaction assessed by change in Diabetes Technology Questionnaire 'current' (ΔDTQ-current) score at 12-weeks (study-end). Secondary outcomes included ΔDTQ-current following extension and other participant-reported outcomes (PROs) measuring quality of life, burden of disease treatment, glycemic and device-related outcomes at 12-weeks (study-end) and 24-weeks (end-extension).
Results: Treatment satisfaction improved more in Omnipod group vs. Usual Care group (ΔDTQ-current score of 16.4 [21.2] vs. 0.0 [12.8]; p < 0.001) at study-end. Significantly greater improvements in other PROs and HbA1c were also observed. Improvements in DTQ-current and other PROs comparing study-end and end-extension were similar. While %TIR change from baseline did not differ at study-end (-2.0 [12.7] %), it was significantly greater at end-extension (5.6 [10.9] %; p = 0.016).
Conclusions: Omnipod DASH System resulted in greater treatment satisfaction at 12 weeks in adults with type 1 diabetes using SMBG which was sustained after 24 weeks of device use without compromising sleep quality and fear of hypoglycemia. Improvements in glycemia were also observed.
(© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.)